Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2704
Source ID: NCT00266240
Associated Drug: Gk Activator (2)
Title: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: GK Activator (2)|DRUG: Placebo
Outcome Measures: Primary: HbA1c mean change from baseline, compared to placebo., Week 12 | Secondary: Additional parameters of glycemic and lipid control., Week 12|AEs, laboratory parameters., Throughout study|Pharmacokinetic and exposure-response relationship, Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 267
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2005-11
Completion Date: 2007-05
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Tucson, Arizona, 85723, United States|Pine Bluff, Arkansas, 71603, United States|Chula Vista, California, 91911, United States|Spring Valley, California, 91978, United States|West Hills, California, 91307, United States|Hollywood, Florida, 33021, United States|Atlanta, Georgia, 30308, United States|Binghamton, New York, 13901, United States|Fayetteville, North Carolina, 28304, United States|Statesville, North Carolina, 28625, United States|Winston-salem, North Carolina, 27103, United States|Springdale, Ohio, 45246, United States|Oklahoma City, Oklahoma, 73112, United States|Medford, Oregon, 97504, United States|Beaver, Pennsylvania, 15009, United States|Tipton, Pennsylvania, 16684, United States|Mount Pleasant, South Carolina, 29464, United States|Plano, Texas, 75093, United States|Renton, Washington, 98055, United States|Dimitrovgrad, 6400, Bulgaria|Pleven, 5800, Bulgaria|Ruse, 7002, Bulgaria|Sofia, 1233, Bulgaria|Sofia, 1303, Bulgaria|Sofia, 1431, Bulgaria|Sofia, 1606, Bulgaria|Zagreb, 10000, Croatia|Guatemala City, 01015, Guatemala|Budapest, 1083, Hungary|Budapest, 1088, Hungary|Gyor, 9024, Hungary|Kecskemet, 6000, Hungary|Chihuahua, 31238, Mexico|Cuernavaca, 62250, Mexico|Durango, 34070, Mexico|Mexico City, 11650, Mexico|Mexico City, 14050, Mexico|Mexico City, 14610, Mexico|Mexico-city, 06700, Mexico|Bialystok, 15-276, Poland|Gdansk, 80-757, Poland|Gorzow, 66-400, Poland|Krakow, 31-121, Poland|Wroclaw, 50-088, Poland
URL: https://clinicaltrials.gov/show/NCT00266240

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress